This early-phase trial is testing an oral chemotherapy drug called azacitidine (CC-486) in 11 adults with a rare type of leukemia (T-LGLL) that has come back or not responded to prior treatment. The study aims to find the best dose and see how well the drug works at shrinking or …
Phase: PHASE1, PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC